\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
CAMBRIDGE, Mass. , July 12, 2022–(BUSINESS WIRE)–VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company focused on immunology in search of powerful disease prevention and treatment, announced that John Dillman has been named the company’s Chief Commercial Officer. Dillman will be guilty of leading VBI’s advertising strategy, sales and sales operations, in addition to advertising the triple hepatitis B (HBV) vaccine, PreHevbrio™ [hepatitis B vaccine (recombinant)].
“Having worked with John for over two years in his role as Chief Commercial Officer of Syneos Health, our spouse in marketing PreHevbrio in the U. S. “In the U. S. , it is a pleasure to announce your appointment as Chief Commercial Officer,” said Jeff Baxter, VBI President and Chief Executive Officer. With this appointment, John will continue to work heavily with the Syneos Health team, ensuring continuity and alignment of strategy and execution for PreHevbrio, while also helping to shape the trajectory of our development pipeline at any given time. Early stage. “
John Dillman added: “It has been a privilege to work with Syneos Health and VBI for the past two years, and I look forward to continuing to contribute to the commercial strategy and sale of PreHevbrio. More broadly, I am very pleased to be able to sign up for VBI. team control at such an exciting time for the company, with several steps to come. VBI’s commitment to public fitness and unmet medical desires is one I am firmly on and have worked on for much of my career. .
Lee Taurman, Executive Vice President, Full Service Commercial, Syneos Health, said, “John’s appointment to VBI is a testament to our successful and ongoing collaboration with VBI. Our purpose over the past few years of partnership has been to help VBI build an effective, full-service commercialization solution to assist in the launch of its HBV antigen 3 vaccine. with best-in-class groups and resources. »
As part of the company’s advertising component with Syneos Health, with whom VBI has been operating since 2019, Mr. Dillman served as Syneos Health’s chief commercial officer for VBI, orchestrating the fully incorporated commercial projects committed to PreHevbrio’s advertising launch in the U. S. UU. Sr. . Dillman has been very concerned about developing VBI’s overall business operations strategy through market access, sales, and marketing efforts. Prior to joining Syneos Health, Mr. Dillman spent 17 years at Sanofi Pasteur, the human vaccines business of the Sanofi Group, in sales and marketing leadership roles. His most recent position was Vice President of Sales, where he was responsible for leading and overseeing the sales force, sales marketing and training, and telesales organization, with full functions for P.
About Hepatitis B
Hepatitis B is one of the world’s largest infectious disease threats, with more than 290 million people infected worldwide. HBV infection is the leading cause of liver disease and, with existing treatments, is very difficult to cure, and many patients develop liver cancer. . An estimated 900,000 other people die each year from chronic HBV headaches, such as liver decompensation, cirrhosis, and hepatocellular carcinoma.
About PreHevbrio™
The VBI hepatitis B vaccine is the 3-antigen hepatitis B vaccine, consisting of the 3 surface antigens of the hepatitis B virus: S, pre-S1 and pre-S2. It is approved for use in the United States, the European Union/European Economic Area, the United Kingdom, and Israel. The names of the logos of this vaccine are: PreHevbrio™ (USA). USA), PreHevbri™ (EU/EEA/UK) and Sci-B-Vac® (Israel).
Visit www. PreHevbrio. com for vital U. S. protective data. U. S. For PreHevbrio ™ [Hepatitis B Vaccine (Recombinant)], or Review Complete U. S. Prescribing Data. USA
The full European summary of product features for PreHevbri is available on the EMA online page in www. ema. europa. eu and on the UK MHRA online page in products. mhra. gov. uk.
Indication from USA
PreHevbrio is indicated for the prevention of infections across all known subtypes of the hepatitis B virus. PreHevbrio is approved for use in adults aged 18 and older.
US Important Security Information (ISI)
Do not give PreHevbrio to others with a history of a severe allergic reaction (such as anaphylaxis) after a previous dose of any hepatitis B vaccine or any component of PreHevbrio.
Appropriate medical treatment and supervision should be available to manage imaginable anaphylactic reactions after management of PreHevbrio.
Immunocompromised people, in addition to those receiving immunosuppressive therapy, would possibly have a decreased immune reaction to PreHevbrio.
PreHevbrio may not prevent hepatitis B infection, which has a long incubation period, in other people who have an undetected hepatitis B infection at the time of vaccine administration.
The maximum non-unusual adverse reactions (> 10%) in older adults aged 18 to 44 years, adults over forty-five to 64 years, and adults over 65 years were pain and tenderness at the injection site, myalgia, fatigue and headache.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women who obtained a PreHevbrio pregnancy. Women who obtain a PreHevbrio pregnancy are encouraged to call 1-888-421-8808 (toll-free).
For SUSPECTED ADVERSE REACTIONS, contact VBI Vaccines at 1-888-421-8808 (toll-free) or VAERS at 1-800-822-7967 or www. vaers. hhs. gov.
See full prescribing information.
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company focused on immunology in pursuit of potent disease prevention and treatment. Through its state-of-the-art technique for virus-like waste (“VLP”), adding the patented wrapped VLP platform (“eVLP”), VBI is developing candidate vaccines that mimic the herbal presentation of viruses, designed to elicit the innate strength of the human immune system. as well as competitive cancers, adding glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with studio operations in Ottawa, Canada, and a studio and production facility in Rehovot, Israel.
For more information, www. vbivaccines. com.
Cautionary Note on Forward-Looking Information
Certain statements in this press release that are forward-looking and not statements of past fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking data within the meaning of the law. Canadian. securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve dangers and uncertainties that may also materially affect the effects of the Company’s operations. These forward-looking statements are based on control’s ideals, as well as the assumptions made through control and the data that exist to obtain it. Actual effects may also differ materially from those weighted through forward-looking statements due to certain factors, including, but not limited to, the impact of general economic, political or publicity situations in the United States or internationally. ; the effect of the current COVID-19 pandemic on our clinical studies, manufacturing, business plan and the global economy; the ability to effectively manufacture and advertise PreHevbrio/PreHevbri; the ability to identify that potential products are effective or safe in preclinical or clinical trials; the ability to identify or maintain collaborations on the progression of candidate projects and PreHevbrio/PreHevbri publicity; the ability to download appropriate or mandatory regulatory approvals to advertise potential products; the ability to offload long-term financing for working capital and progression products and to offload such financing on moderate advertising terms; the Company’s ability to manufacture product applicants on an advertising scale or in collaboration with third parties; adjustments in the duration and nature of the competitors; the ability to retain key executives and scientists; and the ability to secure and enforce similar legal rights to the Company’s products. A discussion of those and other factors, aggregating dangers and uncertainties relating to the Company, is set forth in the Company’s filings with the SEC and Canadian securities regulators, adding its Annual Report on Form 10. -K filed with the SEC on March 7, 2022, and filed with the Canadian Security Government on sedar. com on March 7, 2022, as possibly supplemented or modified through the company’s quarterly reports on Form 10-Q. Given these dangers, uncertainties and factors, you are cautioned not to place undue reliance on these forward-looking statements, which are qualified in their entirety by this cautionary statement. All forward-looking statements made in this document are based on our existing expectations and we assume no legal responsibility or duty to update or revise any forward-looking statements for any reason, except as required by law.
See the businesswire. com edition: https://www. businesswire. com/news/home/20220712005181/en/
Contacts
Contact VBI Nicole AndersonDirector of Corporate Communications